book a demo
Current Vacancies
Home > Our latest webinars
Sign up for an upcoming live webinar or view our archive of previous broadcasts below, available to view on demand. All the latest webinars from Fluidic Analytics, covering a range of topics from measuring antibody affinity in serum to Monitoring of SMALP nanodisc formation, to quantifying the stoichiometry and binding affinity of protein–protein interactions in complex backgrounds.
Dr. Colleen Kelly, a renowned postdoctoral researcher from the Previs Lab at the University of Vermont, will discuss cellular and molecular methods used to study myosin.
Our expert speaker will describe how the combination of Microfluidic Diffusional Sizing (MDS) and fluorescence imaging techniques was utilized to provide evidence of a folded conformation of cytosolic cardiac myosin, further advancing our understanding of its dynamics in vivo.
In the webinar Dr Kelly outlines:
This webinar, the second part of a 2-part mini-webinar series, was presented by Sandro Keller Full Professor and Head of the Biophysics Division at the Institute of Molecular Biosciences (IMB) at the University of Graz, Austria
In the webinar Sandro:
This webinar, the first part of a 2-part mini-webinar series, was presented by Sebastian Fiedler, Head of Applications at Fluidic Analytics.
In the webinar Sebastian covered the Fluidity One-M:
This webinar was presented by Dr. Sean Devenish Head of Technical Support and Field Applications at Fluidic Analytics.
The webinar covers how the deep characterization of humoral responses enabled by MDS is particularly valuable and how:
This webinar was presented by Sebastian Fiedler, Lead Application Scientist at Fluidic Analytics.
In the webinar Sebastian covered how the Fluidity One-M was used by Lund University, Sweden to “obtain unique information that could not have been obtained with other technologies*” including how our technology Determines affinity of interaction (KD), size, and stoichiometry of the complex, all in a single experiment; Provides painless characterisation of disordered proteins or higher-order complexes under immobilisation-free conditions; Reveals a clear picture of the overall mechanism of action between different species by understanding binding.
Understanding the nature of the immune response that leads to recovery from severe disease is key to developing effective treatments for COVID-19. In this webinar, Professor Akiko Iwasaki will discuss immune responses in COVID-19 patients with moderate and severe disease. She will compare viral load, immune phenotype and cytokines that are predictive of mortality, and discuss signatures of cytokines and growth factors that associate with recovery vs. disease exacerbation.
In this webinar, Prof. Linse discusses new methods that have yielded new insights into the mechanisms of action of four clinical-stage anti-Abeta antibodies: aducanumab, gatenerumab, bapineuzumab and solanezumab. Kinetic analyses were combined with binding measurements performed using microfluidic diffusional sizing (MDS) to quantify the influence of these antibodies on the aggregation kinetics and on the production of oligomeric aggregates. It was demonstrated that these effects were linked to the affinity and stoichiometry of each antibody for monomeric and fibrillar forms of Abeta. These results reveal that, uniquely among these four antibodies, aducanumab dramatically reduces the flux of Abeta oligomers.
Prof. Adriano Aguzzi outlines the challenge in understanding the humoral immune response to COVID‑19, and therefore, predicting the degree of immune protection resulting from previous infection, vaccination and other treatments.
We present a new type of rapid assay that is based on quantifying these protein interactions and provides functional insights.
Detecting antibodies that confer effective immunity is crucially important in the fight against SARS-CoV-2.
Measuring antibody affinity in serum – it’s not as trivial as it sounds
We explore the differences between Affinity vs Avidity and hopefully dispel the vagueness you feel next time you come across them in a paper
MDS is an ideal tool to monitor SMALP nanodisc formation discover why in this webinar
Determination of binding affinity and stoichiometry of protein interactions without prior knowledge of the structure
Get in touch, our applications scientists will be happy to discuss your application requirements with you.
This webinar details new methods that have yielded new insights into the mechanisms of action of four clinical-stage anti-Abeta antibodies: aducanumab, gatenerumab, bapineuzumab and solanezumab. Kinetic analyses were combined with binding measurements performed using microfluidic diffusional sizing (MDS) to quantify the influence of these antibodies on the aggregation kinetics and on the production of oligomeric aggregates. It was demonstrated that these effects were linked to the affinity and stoichiometry of each antibody for monomeric and fibrillar forms of Abeta. These results reveal that, uniquely among these four antibodies, aducanumab dramatically reduces the flux of Abeta oligomers.
In this webinar, Prof. Linse discusses: